Nurix Therapeutics Inc (NRIX) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Nurix Therapeutics Inc stock $13.31, price $14.73, that is 9.6% below the price, quality 34 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Nurix Therapeutics Inc
NRIX · USExpensive (fair value 10% below the price) and weak company, but rising price: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.
How to read this chart
60‑month range $4.25 – $36.69 · fair‑value band $9.98 – $16.64 · the $14.73 price screens above the $13.31 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.
Every Wednesday you see whether Nurix Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases.
Show moreShow less
The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications.
It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases.
The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates.
The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
Stock analysis
Nurix Therapeutics Inc (NRIX) currently trades at $14.73, while our estimate is $13.31, 10% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $9.98 (bear) to $16.64 (bull), the price of $14.73 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 34/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Nurix Therapeutics Inc reported revenue of $84.0M in FY2025 versus $29.8M in FY2021, a compound +29.6%/yr. Reported net income was −$264M in FY2025.
Key figures
Market cap $2.9B Mid · P/E ratio 6.1 · P/S ratio 2.24 · EPS (TTM) $2.43 · Net margin 42.0% · Return on equity 44.0% · Return on assets (EBIT) −37.2% (5-year average) · Operating margin 83.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 68 out of 100 (low confidence).
What moves the price
The share trades about 47% below its 52-week high and 16% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −10%, NRIX screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, 4 officers or directors sold shares worth $3.7M and none bought.
- SaleHans van HouteChief Financial Officer7× since Jan 30, 2026: 35,313 shares, avg. $18.84$665,447Nov 4, 2026
- SaleChristine RingChief Legal Officer19× since Nov 24, 2025: 197,626 shares, avg. $19.67$3.9MNov 3, 2026
- SaleGwenn HansenChief Scientific Officer9× since Jan 30, 2026: 34,130 shares, avg. $22.20$757,795Nov 2, 2026
- SaleJulia P GregoryDirector22,583 shares at $23.40$528,528Oct 14, 2026
Plus 17 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗
Revenue & earnings trend
Earlier news
- Is Early B Cell Cancer Data Altering The Investment Case For Nurix Therapeutics (NRIX)?
- Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL a
- Nurix, Sanofi Diverge — And One Breaks Out — On A Shocking Eczema Development
- Nurix Therapeutics stock tumbles on Sanofi program termination
Compare Nurix Therapeutics Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Debt-to-equity by industry
- Price/FCF by industry
- Stock screener with 62 metrics
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs NRIX |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs NRIX |
| Samsung Biologics Co 207940 | 1,423,000 KRW | 1,552,100 KRW | +9% | vs NRIX |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs NRIX |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs NRIX |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs NRIX |
| BeOne Medicines AG 6160 | HK$249.40 | HK$152.92 | −39% | vs NRIX |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs NRIX |
| Celltrion, Inc 068270 | 214,500 KRW | 74,945 KRW | −65% | vs NRIX |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs NRIX |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Nurix Therapeutics Inc (NRIX) overvalued or undervalued?
What is the fair value of NRIX?
What is the quality score of NRIX?
What is the price target for Nurix Therapeutics Inc (NRIX)?
What is the Nurix Therapeutics Inc stock forecast for 2026?
What is the intrinsic value of Nurix Therapeutics Inc (NRIX)?
Is Nurix Therapeutics Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of NRIX?
How much is Nurix Therapeutics Inc worth?
What do the bullish and bearish scenarios say about NRIX?
What is the P/E ratio of NRIX?
How solid is the balance sheet of Nurix Therapeutics Inc (NRIX)?
How far is NRIX from its 52-week high?
Which stocks are comparable to Nurix Therapeutics Inc?
Is Nurix Therapeutics Inc stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Nurix Therapeutics Inc (NRIX)?
What should I pay attention to with Nurix Therapeutics Inc right now?
Key figures of Nurix Therapeutics Inc
How large is the market capitalisation of Nurix Therapeutics Inc (NRIX)?
What is the P/S ratio of Nurix Therapeutics Inc (NRIX)?
What are the earnings per share of Nurix Therapeutics Inc (NRIX)?
What is the net margin of Nurix Therapeutics Inc (NRIX)?
What is the return on equity of Nurix Therapeutics Inc (NRIX)?
What is the EBIT return on assets of Nurix Therapeutics Inc (NRIX)?
What is the operating margin of Nurix Therapeutics Inc (NRIX)?
How fast is revenue growing at Nurix Therapeutics Inc (NRIX)?
How much free cash flow does Nurix Therapeutics Inc (NRIX) generate?
How much net cash does Nurix Therapeutics Inc (NRIX) hold?
Watch Nurix Therapeutics Inc in the live analysis
One click puts Nurix Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.